BNP Paribas Arbitrage SA Sells 38,096 Shares of Edwards Lifesciences Corporation (EW)

BNP Paribas Arbitrage SA lowered its stake in Edwards Lifesciences Corporation (NYSE:EW) by 28.5% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 95,710 shares of the medical research company’s stock after selling 38,096 shares during the period. BNP Paribas Arbitrage SA’s holdings in Edwards Lifesciences Corporation were worth $11,317,000 at the end of the most recent reporting period.

A number of other hedge funds have also recently bought and sold shares of the company. Sabal Trust CO raised its stake in Edwards Lifesciences Corporation by 0.5% in the second quarter. Sabal Trust CO now owns 2,934 shares of the medical research company’s stock valued at $347,000 after buying an additional 14 shares during the period. Alps Advisors Inc. raised its stake in Edwards Lifesciences Corporation by 0.3% in the second quarter. Alps Advisors Inc. now owns 5,102 shares of the medical research company’s stock valued at $603,000 after buying an additional 14 shares during the period. Alexandria Capital LLC raised its stake in Edwards Lifesciences Corporation by 1.7% in the second quarter. Alexandria Capital LLC now owns 1,146 shares of the medical research company’s stock valued at $136,000 after buying an additional 19 shares during the period. Rehmann Capital Advisory Group raised its stake in Edwards Lifesciences Corporation by 1.6% in the first quarter. Rehmann Capital Advisory Group now owns 3,393 shares of the medical research company’s stock valued at $319,000 after buying an additional 55 shares during the period. Finally, M Holdings Securities Inc. raised its stake in Edwards Lifesciences Corporation by 1.5% in the first quarter. M Holdings Securities Inc. now owns 4,132 shares of the medical research company’s stock valued at $389,000 after buying an additional 62 shares during the period. 84.67% of the stock is currently owned by hedge funds and other institutional investors.

Shares of Edwards Lifesciences Corporation (NYSE EW) opened at 113.11 on Monday. The firm has a market capitalization of $23.88 billion, a P/E ratio of 34.31 and a beta of 0.63. Edwards Lifesciences Corporation has a 52 week low of $81.12 and a 52 week high of $121.75. The firm’s 50-day moving average is $116.42 and its 200-day moving average is $106.02.

Edwards Lifesciences Corporation (NYSE:EW) last announced its quarterly earnings data on Wednesday, July 26th. The medical research company reported $1.08 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.88 by $0.20. Edwards Lifesciences Corporation had a return on equity of 27.17% and a net margin of 22.16%. The business had revenue of $842 million for the quarter, compared to analysts’ expectations of $839.16 million. During the same period in the previous year, the business posted $0.76 EPS. The firm’s quarterly revenue was up 10.9% compared to the same quarter last year. Equities analysts anticipate that Edwards Lifesciences Corporation will post $3.78 EPS for the current year.

WARNING: “BNP Paribas Arbitrage SA Sells 38,096 Shares of Edwards Lifesciences Corporation (EW)” was originally published by Sports Perspectives and is the property of of Sports Perspectives. If you are reading this report on another website, it was stolen and republished in violation of U.S. & international trademark & copyright law. The legal version of this report can be accessed at https://sportsperspectives.com/2017/08/21/bnp-paribas-arbitrage-sa-sells-38096-shares-of-edwards-lifesciences-corporation-ew.html.

Several research firms have issued reports on EW. Zacks Investment Research lowered shares of Edwards Lifesciences Corporation from a “buy” rating to a “hold” rating in a research report on Thursday, May 18th. BidaskClub lowered shares of Edwards Lifesciences Corporation from a “strong-buy” rating to a “buy” rating in a research report on Wednesday, July 19th. Bank of America Corporation upped their price target on shares of Edwards Lifesciences Corporation from $140.00 to $150.00 and gave the stock a “buy” rating in a research report on Thursday, July 27th. SunTrust Banks, Inc. upped their price target on shares of Edwards Lifesciences Corporation to $14.00 and gave the stock a “buy” rating in a research report on Monday, July 17th. Finally, Royal Bank Of Canada increased their price objective on shares of Edwards Lifesciences Corporation from $116.00 to $120.00 and gave the company an “outperform” rating in a research report on Wednesday, April 26th. Five investment analysts have rated the stock with a hold rating, seventeen have given a buy rating and one has given a strong buy rating to the stock. The stock presently has a consensus rating of “Buy” and an average price target of $120.18.

In other news, CEO Michael A. Mussallem sold 32,900 shares of the company’s stock in a transaction dated Wednesday, August 9th. The stock was sold at an average price of $115.99, for a total transaction of $3,816,071.00. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, VP Catherine M. Szyman sold 4,681 shares of the company’s stock in a transaction dated Monday, July 31st. The shares were sold at an average price of $115.78, for a total value of $541,966.18. The disclosure for this sale can be found here. Insiders sold a total of 149,281 shares of company stock worth $17,331,446 over the last 90 days. 2.13% of the stock is currently owned by company insiders.

Edwards Lifesciences Corporation Company Profile

Edwards Lifesciences Corporation is a manufacturer of heart valve systems and repair products used to replace or repair a patient’s diseased or defective heart valve. The Company is engaged in patient-focused innovations for structural heart disease and critical care monitoring. Its segments include United States, Europe, Japan and Rest of World.

Want to see what other hedge funds are holding EW? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Edwards Lifesciences Corporation (NYSE:EW).

Institutional Ownership by Quarter for Edwards Lifesciences Corporation (NYSE:EW)

Receive News & Ratings for Edwards Lifesciences Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences Corporation and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply